As the first international research-oriented hospital in China, Beijing GoBroad Hospital is dedicated to solving complex and critical illness problems. It closely integrates "research" and "clinical" functions, forming a specialized clinical trial team. Led by top researchers (PIs) and supported by a dedicated research team, they are committed to conducting clinical trials that meet international standards.

Currently, Beijing GoBroad Hospital is conducting a series of clinical trial projects, with a focus on gastrointestinal and hematologic malignancies. If you're interested in participating, you can add the corresponding research doctor to assess whether you meet the enrollment criteria.

 

Gastrointestinal Oncology Clinical Trial Recruitment

1. Clinical Trial: A Phase III study comparing the safety and efficacy of Lutetium-177 ([177Lu]) oxytocin injection versus long-acting octreotide in adult patients with gastrointestinal pancreatic neuroendocrine tumors.
2. Recruitment Criteria: Patients diagnosed with low or intermediate grade (G1 or G2) inoperable, locally advanced, or metastatic gastrointestinal pancreatic neuroendocrine tumors, who have previously undergone treatment with standard dose somatostatin analogs and showed progression.Clinical Trial: A Phase III study evaluating the efficacy and safety of ASK589 injection or placebo in combination with CAPOX (Oxaliplatin and Capecitabine) and PD-1 inhibitors as first-line treatment for CLDN18.2 positive, inoperable, locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma.
3. Recruitment Criteria: Patients with histologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma, and who have been diagnosed with advanced, recurrent, or metastatic disease by imaging.Clinical Trial: A Phase III randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of M108 monoclonal antibody injection versus placebo in combination with CAPOX (Oxaliplatin and Capecitabine) for the treatment of locally advanced, inoperable, or metastatic CLDN18.2 positive, HER2 negative, PD-L1 CPS<5 gastric or gastroesophageal junction adenocarcinoma.
4. Recruitment Criteria: Patients with advanced gastric or gastroesophageal junction adenocarcinoma who have not previously received systemic treatment.Clinical Trial: An open-label, multi-center Phase Ib/II study evaluating the safety and efficacy of LBL-024 in combination with etoposide and platinum-based chemotherapy as first-line treatment for advanced neuroendocrine carcinoma (NEC).

Recruitment Criteria: Patients with histologically and/or cytologically confirmed, inoperable, locally advanced, or metastatic extrapulmonary NEC at the Phase II stage.

 

If you are interested in participating in gastrointestinal oncology clinical trials, please contact us. Our research doctor will preliminarily assess whether you meet the enrollment criteria for this study. We will strictly maintain the confidentiality of your personal information and welcome your registration and participation.

For gastrointestinal oncology research, please add the research doctor's WeChat for an initial review.

 

Lymphoma and Myeloma Department Clinical Trial Recruitment

 

1.Clinical Trial: A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of JL1132 in the treatment of relapsed/refractory hematologic tumors.

Patient Recruitment: Patients diagnosed with relapsed/refractory hematologic malignancies (multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome) who have failed prior standard treatment regimens, have no standard treatment options, or cannot tolerate existing treatments.

 

2.Clinical Trial: A Phase I clinical study to evaluate the safety, tolerability, and efficacy of the universal LUCAR-G39P cell therapy targeting CD19/CD20 dual antigens in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.

Patient Recruitment: Patients with histologically confirmed diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or indolent lymphoma undergoing histological transformation to diffuse large B-cell lymphoma.

 

3.Clinical Trial: A multicenter clinical study on the use of GPRC5D-targeted chimeric antigen receptor (CAR) T-cell injection for the treatment of relapsed/refractory multiple myeloma.

Patient Recruitment: Patients with measurable lesions in multiple myeloma who have failed prior treatments involving at least three different drug classes, including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies.

 

If you are interested in participating in the lymphoma and myeloma clinical trials, please contact us. Our research doctor will preliminarily assess whether you meet the enrollment criteria for this study. We will strictly maintain the confidentiality of your personal information and welcome your registration and participation.

For lymphoma and myeloma research, please add the research doctor's WeChat for an initial review.